Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Albendazole

FDA-approved product (tablet, oral), marketed as Albendazole, Albenza.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Albendazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cysticercosis
  • Helminthiasis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzimidazole derivatives
FDA pharmacologic class
Anthelmintic FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02CA03; FDA class Anthelmintic

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Albendazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Albendazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG

    NCT03268252 · start 2012-06

    Registered record
    Registry ID
    NCT03268252
    Conditions
    Lymphatic Filariasis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-06
    Completion
    2018-12
    Enrolment
    3,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphatic Filariasis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population

    NCT01755637 · start 2012-04

    Registered record
    Registry ID
    NCT01755637
    Conditions
    Helminthiasis
    Interventions
    Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-06
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelminthiasis
    InterventionAlbendazole
    PhasePhase 1
    Registry statusCompleted

  • IVM Alone vs ALB + IVM Against Onchocerciasis

    NCT03238131 · start 2012-04

    Registered record
    Registry ID
    NCT03238131
    Conditions
    Onchocerciasis
    Interventions
    Ivermectin; Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-04
    Completion
    2016-10
    Enrolment
    272

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    InterventionIvermectin; Albendazole
    PhasePhase 3
    Registry statusCompleted

  • Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

    NCT02366884 · start 2011-07-26

    Registered record
    Registry ID
    NCT02366884
    Conditions
    Neoplasms
    Interventions
    Anti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-07-26
    Completion
    2023-12-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionAnti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
    PhasePhase 2
    Registry statusUnknown

  • Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis

    NCT01905423 · start 2011-05

    Registered record
    Registry ID
    NCT01905423
    Conditions
    Lymphatic Filariasis; Soil Transmitted Helminth Infections
    Interventions
    Albendazole (annual); Diethylcarbamazine (annual); Albendazole (semiannual); Diethylcarbamazine (semiannual)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-05
    Completion
    2015-12
    Enrolment
    17,108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphatic Filariasis; Soil Transmitted Helminth Infections
    InterventionAlbendazole (annual); Diethylcarbamazine (annual); Albendazole (semiannual); Diethylcarbamazine (semiannual)
    PhaseNot recorded
    Registry statusCompleted

  • Management of Soil-transmitted Helminthiasis and Strongyloidiasis

    NCT01308268 · start 2010-12

    Registered record
    Registry ID
    NCT01308268
    Conditions
    Helminthiasis; Strongyloides Stercoralis Infection
    Interventions
    Ivermectin + Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2010-12
    Completion
    2012-04
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelminthiasis; Strongyloides Stercoralis Infection
    InterventionIvermectin + Albendazole
    PhaseNot applicable
    Registry statusUnknown

  • Education Intervention to Reduce Helminth Infections and Absenteeism in Grade 5 School-children

    NCT01085799 · start 2010-04

    Registered record
    Registry ID
    NCT01085799
    Conditions
    Infections
    Interventions
    Health Education Intervention
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-10
    Enrolment
    1,101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections
    InterventionHealth Education Intervention
    PhaseNot applicable
    Registry statusCompleted

  • Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)

    NCT00441285 · start 2010-01

    Registered record
    Registry ID
    NCT00441285
    Conditions
    Neurocysticercosis; Epilepsy
    Interventions
    Praziquantel; Albendazole; ABZ Placebo; PZQ Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-01
    Completion
    2013-09
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurocysticercosis; Epilepsy
    InterventionPraziquantel; Albendazole; ABZ Placebo; PZQ Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Community Trial for Visceral Leishmaniasis (VL)

    NCT01069198 · start 2009-10

    Registered record
    Registry ID
    NCT01069198
    Conditions
    Visceral Leishmaniasis
    Interventions
    Albendazole, Iron, Zinc and Vitamin A; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-10
    Completion
    2010-11
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionAlbendazole, Iron, Zinc and Vitamin A; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children

    NCT01087099 · start 2009-01

    Registered record
    Registry ID
    NCT01087099
    Conditions
    Infections With Soil-Transmitted Helminths (STH)
    Interventions
    Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-03
    Enrolment
    1,750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections With Soil-Transmitted Helminths (STH)
    InterventionAlbendazole
    PhasePhase 4
    Registry statusCompleted

  • Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression

    NCT00507221 · start 2008-02

    Registered record
    Registry ID
    NCT00507221
    Conditions
    HIV Infections; Helminthiasis
    Interventions
    Albendazole; Praziquantel; Current standard of care in Kenya
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-02
    Completion
    2011-10
    Enrolment
    948

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Helminthiasis
    InterventionAlbendazole; Praziquantel; Current standard of care in Kenya
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy of Drug Combinations Against Schistosomiasis

    NCT01050374 · start 2007-10

    Registered record
    Registry ID
    NCT01050374
    Conditions
    Parasitic Diseases
    Interventions
    albendazole + praziquantel; mebendazole + praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-10
    Completion
    2008-10
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParasitic Diseases
    Interventionalbendazole + praziquantel; mebendazole + praziquantel
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy of Drug Combinations Against Trichuris Trichiura

    NCT01050452 · start 2007-10

    Registered record
    Registry ID
    NCT01050452
    Conditions
    Parasitic Diseases
    Interventions
    albendazole; mebendazole; ivermectin; albendazole + ivermectin; mebendazole + ivermectin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-10
    Completion
    2009-08
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParasitic Diseases
    Interventionalbendazole; mebendazole; ivermectin; albendazole + ivermectin +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy of Drug Combinations Against Triple Infections

    NCT01050517 · start 2007-10

    Registered record
    Registry ID
    NCT01050517
    Conditions
    Parasitic Diseases
    Interventions
    albendazole + ivermectin + praziquantel; albendazole + ivermectin + (1 week later) praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-10
    Completion
    2007-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParasitic Diseases
    Interventionalbendazole + ivermectin + praziquantel; albendazole + ivermectin + (1 week later) praziquantel
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming in Vietnamese School Children

    NCT00728273 · start 2007-01

    Registered record
    Registry ID
    NCT00728273
    Conditions
    Healthy
    Interventions
    worm treatment and multiple micronutrient fortified biscuits
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-01
    Completion
    2007-06
    Enrolment
    510

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionworm treatment and multiple micronutrient fortified biscuits
    PhasePhase 2
    Registry statusCompleted